Last $102.21 USD
Change Today -1.01 / -0.98%
Volume 4.0M
JNJ On Other Exchanges
Symbol
Exchange
New York
Mexico
Sao Paulo
Bogota
As of 2:02 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

johnson & johnson (JNJ) Snapshot

Open
$103.10
Previous Close
$103.22
Day High
$103.10
Day Low
$101.81
52 Week High
11/13/14 - $109.49
52 Week Low
03/3/14 - $90.83
Market Cap
284.0B
Average Volume 10 Days
8.7M
EPS TTM
$5.97
Shares Outstanding
2.8B
EX-Date
02/20/15
P/E TM
17.1x
Dividend
$2.80
Dividend Yield
2.74%
Current Stock Chart for JOHNSON & JOHNSON (JNJ)

johnson & johnson (JNJ) Details

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON’S brand name; oral care products under the LISTERINE brand name; skin care products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, LE PETITE MARSEILLAIS, LUBRIDERM, NEUTROGENA, and RoC brand names; women’s health products, such as sanitary pads under the STAYFREE and CAREFREE, and o.b. tampon brand names; wound care products, including adhesive bandages and first aid products under the BAND-AID and NEOSPORIN brand names; and nutritional products comprising no calorie sweetener under the SPLENDA brand name. This segment also offers over-the-counter medicines, including acetaminophen products under the TYLENOL brand name; cold, flu, and allergy products under the SUDAFED brand name; allergy products under the BENADRYL and ZYRTEC brand names; ibuprofen products under the MOTRIN IB brand name; and heartburn products under the PEPCID brand name. The Pharmaceutical segment provides various products in the areas of immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment offers orthopaedic, and trauma and neurological products; general surgery, and biosurgical and energy products; products to treat cardiovascular disease; infection prevention products; diagnostics products; blood glucose monitoring and insulin delivery products; and disposable contact lenses. The company distributes its products to general public, retail outlets and distributors, wholesalers, hospitals, and health care professionals for prescription use in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.

126,500 Employees
Last Reported Date: 02/24/15
Founded in 1885

johnson & johnson (JNJ) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $1.5M
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $842.3K
Group Worldwide Chairman and Member of Execut...
Total Annual Compensation: $2.7M
Worldwide Chairman of Pharmaceuticals, Chief ...
Total Annual Compensation: $952.9K
Vice President, General Counsel and Member of...
Total Annual Compensation: $542.3K
Compensation as of Fiscal Year 2013.

johnson & johnson (JNJ) Key Developments

Pharmacyclics Reportedly Attracted Interest For Sale

Pharmacyclics Inc. (NasdaqGS:PCYC) intends to sell itself and has attracted interest from the buyers. Johnson & Johnson (NYSE:JNJ) and Novartis AG (SWX:NOVN) have shown interest in acquiring Pharmacyclics, Bloomberg reported. Pharmacyclics could fetch $17 billion-$18 billion from a possible sale, Bloomberg said citing people familiar with the matter. Reuters added that representatives of all three companies declined to comment. Pharmacyclics shares rose 16%.

Johnson & Johnson Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 05:00 PM

Johnson & Johnson Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 05:00 PM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States. Speakers: Shakti Narayan, Sr. Director, Transactions.

J&J Reportedly To Sell Cordis To Cardinal Health

Johnson & Johnson (NYSE:JNJ) (J&J) is planning to sell its Cordis Corporation, and Cardinal Health, Inc. (NYSE:CAH) may be the potential buyer, according to people with knowledge of the matter. A number of other parties are reported to have expressed interest in the acquisition and Cordis may be sold for $2 billion. Spokesmen for J&J and Cardinal declined to comment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JNJ:US $102.20 USD -1.02

JNJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $25.84 USD -0.2699
Merck & Co Inc $58.16 USD -0.42
Novartis AG SFr.95.00 CHF -3.00
Pfizer Inc $34.58 USD -0.1899
Roche Holding AG SFr.260.00 CHF -1.00
View Industry Companies
 

Industry Analysis

JNJ

Industry Average

Valuation JNJ Industry Range
Price/Earnings 18.0x
Price/Sales 3.9x
Price/Book 4.1x
Price/Cash Flow 17.5x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JOHNSON & JOHNSON, please visit www.jnj.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.